Parkinson’s Disease News and Research RSS Feed - Parkinson’s Disease News and Research

Discovery opens new drug development avenues for treating multiple diseases

Discovery opens new drug development avenues for treating multiple diseases

Researchers at the University of California, San Diego School of Medicine have discovered a control switch for the unfolded protein response (UPR), a cellular stress relief mechanism drawing major scientific interest because of its role in cancer, diabetes, inflammatory disorders and several neural degenerative disorders, including Alzheimer's disease, Parkinson's disease, and amyotrophic lateral sclerosis (ALS), otherwise known as Lou Gehrig's disease. [More]
Study: Blood test may help diagnose Fragile X syndrome related disorders in women

Study: Blood test may help diagnose Fragile X syndrome related disorders in women

A blood test may shed new light on Fragile X syndrome related disorders in women, according to a new study published in the March 25, 2015, online issue of Neurology, the medical journal of the American Academy of Neurology. Fragile X is the most common inherited form of intellectual disability and the most frequent genetic cause of autism. [More]
Mexican researcher close to finding a cure for Parkinson's disease

Mexican researcher close to finding a cure for Parkinson's disease

Parkinson's disease, which took world fame after being diagnosed in various personalities such as actor Michael J. Fox, the heavyweight champion Muhammad Ali and the painter Salvador Dalí, could be very close to a cure, thanks to a Mexican researcher which managed to eliminate its neurological effects with an immunosuppressant. [More]
Cumulative genetic risk may underlie many Parkinson’s cases

Cumulative genetic risk may underlie many Parkinson’s cases

Genetic risk for Parkinson’s disease may be due as much to multiple genes with small individual effects as to single high-risk genes, research suggests. [More]
TSRI scientists confirm ribosome assembly as new target for anti-cancer drugs

TSRI scientists confirm ribosome assembly as new target for anti-cancer drugs

Ribosomes, ancient molecular machines that produce proteins in cells, are required for cell growth in all organisms, accomplishing strikingly complex tasks with apparent ease. But defects in the assembly process and its regulation can lead to serious biological problems, including cancer. [More]
Creatine monohydrate disappoints in Parkinson’s disease

Creatine monohydrate disappoints in Parkinson’s disease

Creatine monohydrate fails to live up to its early promise in patients with Parkinson’s disease, show the results of the Long-term Study 1. [More]
Enrollment completed in Pharma Two B's P2B001 Phase IIb study for Parkinson's disease treatment

Enrollment completed in Pharma Two B's P2B001 Phase IIb study for Parkinson's disease treatment

Pharma Two B announced today that enrollment has been completed in the company's Phase IIb study of P2B001 for the treatment of early stage Parkinson's disease. One hundred and forty-nine patients enrolled in the study conducted at 29 clinical sites throughout the US and Israel. [More]
Perceived cost affects placebo response in Parkinson’s disease

Perceived cost affects placebo response in Parkinson’s disease

Patients with Parkinson’s disease may gain a greater benefit from a placebo treatment if they believe it to be expensive, research suggests. [More]
Patients with Parkinson's disease often face difficulties with reduced visual contrast acuity

Patients with Parkinson's disease often face difficulties with reduced visual contrast acuity

Patients with Parkinson's disease (PD) often have difficulties with visual acuity in low-contrast images. Because they may have normal high-contrast vision, this is often overlooked during routine eye exams. In the current issue of the Journal of Parkinson's Disease, researchers report that PD patients had significantly worse vision for low-contrast images at close (40 cm) and far (2 m) distances. Even for high-contrast images, PD patients' vision was deficient at far distances. [More]
UK scientists find new approach to treat Parkinson's disease

UK scientists find new approach to treat Parkinson's disease

UK scientists have developed a peptide that sticks to the protein that causes Parkinson's disease, stopping it from killing brain cells. The research highlights a potential new route for slowing the progress of this incurable disease. [More]
Prexton closes €8.7 million in Series A financing to develop treatments for Parkinson’s disease

Prexton closes €8.7 million in Series A financing to develop treatments for Parkinson’s disease

Prexton Therapeutics, a biopharmaceutical company developing novel therapeutic compounds for the treatment of CNS conditions including Parkinson’s disease, today announces the closing of a Series A financing of €8.7 million ($10 million) co-led by Sunstone Capital and Ysios Capital. [More]
Neurodegenerative disease research using NMR: an interview with Christian Griesinger

Neurodegenerative disease research using NMR: an interview with Christian Griesinger

Christian Griesinger, director of the NMR-based Structural Biology department at the Max-Planck Institute for Biophysical Chemistry, talks about his research into neurodegenerative diseases using NMR to examine the dynamics of disordered proteins. [More]
Saluda Medical receives $10 million in Series B financing

Saluda Medical receives $10 million in Series B financing

Saluda Medical has today announced that it has received $10 million in Series B financing bringing a breakthrough treatment for chronic pain one step closer to reality. [More]
New study finds that statins may not reduce risk for Parkinson's disease

New study finds that statins may not reduce risk for Parkinson's disease

The use of statins may not be associated with lowering risk for Parkinson's disease, according to a new study led by researchers at Penn State College of Medicine and National Institute of Environmental Health Sciences. The findings cast doubts on reports suggesting that the cholesterol-lowering medications may protect against this neurodegenerative brain disorder. [More]

Recent clinical study offers hope for potential Parkinson's disease therapies

Researchers have long sought treatments that can slow the progression of Parkinson's disease. Current treatments have for decades been only symptomatic in nature, supplying the neurotransmitter dopamine, which the dying nerve cells can no longer produce. [More]
Breath test could detect Parkinson’s

Breath test could detect Parkinson’s

The researchers, with funding from Parkinson’s UK and the British Council, will study around 200 people and see if just by looking at their breath they can determine which have Parkinson’s. [More]
Creatine monohydrate disappoints in Parkinson’s disease

Creatine monohydrate disappoints in Parkinson’s disease

Creatine monohydrate fails to live up to its early promise in patients with Parkinson’s disease, show the results of the Long-term Study 1. [More]
'Mad Cow' discovery points to possible neuron killing mechanism behind alzheimer’s and parkinson’s diseases

'Mad Cow' discovery points to possible neuron killing mechanism behind alzheimer’s and parkinson’s diseases

The new study, published recently in the journal Brain, revealed the mechanism of toxicity of a misfolded form of the protein that underlies prion diseases, such as bovine spongiform encephalopathy (“mad cow disease”) and its human equivalent, Creutzfeldt-Jakob disease. [More]

Creatine monohydrate fails to slow clinical progression of Parkinson's disease

Treatment with creatine monohydrate for at least 5 years for patients with early and treated Parkinson disease failed to slow clinical progression of the disease, compared with placebo, according to a study in the February 10 issue of JAMA. [More]
SensiQ Technologies and Inventiva set up a European Center of Excellence in surface plasmon resonance (SPR) technologies

SensiQ Technologies and Inventiva set up a European Center of Excellence in surface plasmon resonance (SPR) technologies

The SPR Center of Excellence is based in Dijon, France. Inventiva’s existing pharmaceutical discovery platform will now include SensiQ SPR technology, which strengthens Inventiva’s current service offering. [More]
Advertisement
Advertisement